Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960763 · ClinicalTrials.gov registry record · Phase 4
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
A Phase 4 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 742
- Enrollment target
- 5
- Study locations
NCT02960763 is a Phase 4 study of Major Depressive Disorder and Treatment-Resistant Depression that has completed, run by Washington University School of Medicine. The registered enrollment target is 742 participants, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (98% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT02960763, a Phase 4 study of Major Depressive Disorder and Treatment-Resistant Depression, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 742 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
Conditions Studied
Interventions
- DRUG Aripiprazole Augmentation
- DRUG Bupropion Augmentation
- DRUG Switch to bupropion
- DRUG Lithium Augmentation
- DRUG Switch to nortriptyline
Study Locations (5)
California
- UCLA Late-Life Mood, Stress, and Wellness Research Program - Los Angeles
Missouri
- Washington University School of Medicine Healthy Mind Lab - St Louis
New York
- Columbia University Adult and Late Life Depression Clinic - New York
Pennsylvania
- UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program - Pittsburgh
Ontario
- Centre for Addiction and Mental Health - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960763
The ClinicalTrials.gov registry entry for NCT02960763 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 742 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (98% higher). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 5 interventions - of which Aripiprazole Augmentation is the first listed.
NCT02960763 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT02960763 about?
NCT02960763 is a clinical study titled "Optimizing Outcomes of Treatment-Resistant Depression in Older Adults". The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
What is the current status of trial NCT02960763?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 742 participants. The study started on 2017-02-24. Estimated completion is 2021-09-01.
What conditions does trial NCT02960763 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression, Late Life Depression, Treatment-Refractory Depression, Geriatric Depression.
What interventions are being tested in trial NCT02960763?
The interventions under investigation include: Aripiprazole Augmentation (DRUG), Bupropion Augmentation (DRUG), Switch to bupropion (DRUG), Lithium Augmentation (DRUG), Switch to nortriptyline (DRUG).
Who is sponsoring clinical trial NCT02960763?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960763 being conducted?
This trial has 5 study locations across California, Missouri, New York, Pennsylvania, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.